Jazz Pharmaceuticals Raises 2026 Revenue Guidance After $1.2B Quarter
Jazz Pharmaceuticals reported record third-quarter revenue of $1.2 billion, up 10% year over year, and raised full-year 2026 total revenue guidance. Net loss included $754 million of acquired IPR&D expense related to Actio.
Jazz Pharmaceuticals reported record third-quarter revenue of $1.2B, up 10% YoY, and raised full-year 2026 total revenue guidance. Net loss included $754M of acquired IPR&D expense related to Actio.Material DetailsContext by AI AnalystThis is a quarterly results update showing continued commercial…